Guardant Health Inc
GH: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$63.00 | Mcky | Pdjhjbwvl |
Guardant Health Releases Strong Preliminary 2022 Results; Maintaining Fair Value Estimate
Guardant Health released preliminary unaudited financial results for 2022. At first glance, even after adjusting near-term assumptions to reflect the outperformance in the fourth quarter, our long-term assumptions would not change much. So we are maintaining our $63 fair value estimate. Shares still appear to be undervalued even after today's high-single-digit rally.